myasthenia gravis

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

News

J&J adds another string to nipocalimab bow with gMG data

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drug

News

UCB on course for approval of gMG drug Rystiggo in EU

UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv

News

UCB bags FDA approval for second myasthenia gravis drug

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope

News

Soliris becomes first drug for paediatric gMG in Europe

AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in

Digital